Literature DB >> 15964656

Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C.

Chun-Jen Liu1, Pei-Jer Chen, Yung-Ming Jeng, Wen-Ling Huang, Wei-Shiung Yang, Ming-Yang Lai, Jia-Horng Kao, Ding-Shinn Chen.   

Abstract

BACKGROUND/AIMS: Adiponectin induces insulin sensitivity and modulates inflammatory responses. We thus studied the implications of adiponectin in patients with chronic hepatitis C virus (HCV) infection inherently linked to insulin resistance.
METHODS: We analyzed the association of serum adiponectin levels with clinical, virologic, and histologic findings in 95 naive Taiwanese patients with chronic hepatitis C before and after antiviral therapy.
RESULTS: At baseline, 14 (15%) of the 95 patients were obese and 26 (27%) had type 2 diabetes mellitus. Fifty-seven patients were infected with HCV genotype 1 and 38 with genotype 2. Steatosis and periportal fibrosis was present in 44 (46%) and 69 (73%), respectively. In multivariate analysis, male gender, insulin resistance, high HCV load and genotype 2 were significantly associated with a lower serum adiponectin level. In contrast, intrahepatic gene expression of adiponectin receptors was higher in genotype 2 compared with genotype 1. Serum adiponectin level did not correlate with other clinical or histologic parameters. After treatment, change of steatosis also did not correlate with the change of adiponectin level (P=0.61).
CONCLUSIONS: Adiponectin correlated with hepatitis C viral factors at both serum and liver tissue levels. The interactions among adiponectin, insulin resistance and chronic HCV infection merit further studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964656     DOI: 10.1016/j.jhep.2005.02.044

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

1.  The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.

Authors:  Ming-Ling Chang; Chia-Jung Kuo; Li-Heng Pao; Chen-Ming Hsu; Cheng-Tang Chiu
Journal:  Virulence       Date:  2017-03-07       Impact factor: 5.882

Review 2.  [Current problems of hepatitis].

Authors:  H P Dienes; U Drebber
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

3.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

Review 4.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

Review 5.  Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.

Authors:  Valentina Peta; Carlo Torti; Natasa Milic; Alfredo Focà; Ludovico Abenavoli
Journal:  World J Hepatol       Date:  2015-01-27

6.  Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis.

Authors:  Emilio González-Reimers; Javier López-Prieto; Geraldine Quintero-Platt; Ricardo Pelazas-González; M Remedios Alemán-Valls; Onán Pérez-Hernández; M José de-la-Vega-Prieto; M Angeles Gómez-Rodríguez; Candelaria Martín-González; Francisco Santolaria-Fernández
Journal:  World J Hepatol       Date:  2016-01-08

7.  Metabolic profiles in patients with chronic hepatitis C: a case-control study.

Authors:  Ching-Sheng Hsu; Chun-Jen Liu; Chen-Hua Liu; Chi-Ling Chen; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2008-02-28       Impact factor: 6.047

8.  High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Chen-Hua Liu; Chi-Lin Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2008-12-02       Impact factor: 6.047

9.  Adiponectin in chronic hepatitis C.

Authors:  Toru Arano; Hayato Nakagawa; Hitoshi Ikeda; Kazuhiko Koike
Journal:  Clin J Gastroenterol       Date:  2013-08-14

10.  Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.

Authors:  Shaikh Mizanoor Rahman; Ishtiaq Qadri; Rachel C Janssen; Jacob E Friedman
Journal:  J Lipid Res       Date:  2009-06-05       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.